 |
|
Effects of Zidovudine Therapy in Minority and Other Subpopulations With Early HIV Infection
Stephen Lagakos, PhD;
Margaret A. Fischl, MD;
Daniel S. Stein, MD;
Lynette Lim, PhD;
Paul Volberding, MD
JAMA. 1991;266(19):2709-2712.
Abstract
| |
Objective.
—The purpose of this study was to determine whether the beneficial effects of zidovudine seen overall in two recently completed placebo-controlled clinical trials are also apparent in blacks, Hispanics, women, and intravenous drug users.
Design.
—Two double-blind placebo-controlled randomized clinical trials, protocols 016 and 019, conducted by the AIDS Clinical Trials Group.
Setting.
—University-based referral centers.
Participants.
—Two thousand forty-eight persons with asymptomatic or mildly symptomatic human immunodeficiency virus infection were analyzed. Of these, 155 were black, 190 were Hispanic, 144 were women, and 221 were intravenous drug users. All randomized subjects were included in the analysis.
Intervention.
—Participants in the AIDS Clinical Trials Group protocol 016 were assigned to receive a placebo or a 1200-mg daily dose of zidovudine. Participants in the AIDS Clinical Trials Group protocol 019 were assigned to receive a placebo, a 500-mg daily dose of zidovudine, or a 1500-mg daily dose of zidovudine.
Main Outcome Measure.
—Progression to AIDS.
Result.
—The rates of progression to AIDS in subjects receiving zidovudine were significantly lower than those in subjects receiving a placebo among blacks (P=.03), whites (relative risk [RR]=2.3, 95% confidence interval [Cl]=1.5 to 3.6, P<.0001), Hispanics (RR=4.4, Cl=1.2 to 16.8, P=.02), non-Hispanics (RR = 2.3, Cl = 1.5 to 3.6, P=.0002), men (RR = 2.5, Cl = 1.6 to 3.8, P<.0001), and non-intravenous drug users (RR = 2.5, CI = 1.6 to 4.0, P<.0001). The rates of disease progression for subjects receiving zidovudine were not statistically different from those receiving placebo for women (RR =3.3, Cl=0.3 to 36.3, P=.31) or for intravenous drug users (RR = 2.0, Cl=0.7 to 6.2, P=.21), however, in both instances the estimated RRs were similar to those for men and nonintravenous drug users.
Conclusions.
—Although the two studies used for this analysis were not specifically designed to assess the effects of zidovudine in each separate subpopulation, the data suggest that the beneficial effects of zidovudine reported for the entire study population also apply to the subpopulations of blacks, Hispanics, women, and intravenous drug users.
(JAMA. 1991;266:2709-2712)
Author Affiliations
From the Department of Biostatistics, Harvard University School of Public Health, Boston, Mass (Drs Lagakos and Lim); the Department of Medicine, University of Miami (Fla), (Dr Fischl); Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Md (Dr Stein); and the Department of Medicine, University of California, San Francisco (Dr Volberding).
Footnotes
Reprint requests to Department of Biostatistics, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115 (Dr Lagakos).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Demographic Characteristics and Survival With AIDS: Health Disparities in Chicago, 1993-2001
Woldemichael et al.
AJPH 2009;99:S118-S123.
ABSTRACT
| FULL TEXT
Effect of Comprehensive Intervention Program on Survival of Patients With Human Immunodeficiency Virus Infection
Laraque et al.
Arch Intern Med 1996;156:169-176.
ABSTRACT
Expanding Prisoners' Access to AIDS-Related Clinical Trials: An Ethical and Clinical Imperative
KELLY
The Prison Journal 1995;75:48-68.
ABSTRACT
A Cohort Study of Drug Users' Compliance With Zidovudine Treatment
Broers et al.
Arch Intern Med 1994;154:1121-1127.
ABSTRACT
Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community
Moore et al.
NEJM 1994;330:763-768.
ABSTRACT
| FULL TEXT
Zidovudine: Five Years Later
McLeod and Hammer
ANN INTERN MED 1992;117:487-501.
ABSTRACT
The Effect of Zidovudine on Patient Subgroups-Reply
Lagakos et al.
JAMA 1992;267:2473-2473.
ABSTRACT
The Effect of Zidovudine on Patient Subgroups
Hamilton et al.
JAMA 1992;267:2472-2473.
ABSTRACT
The Challenge of Minority Recruitment in Clinical Trials for AIDS
El-Sadr and Capps
JAMA 1992;267:954-957.
ABSTRACT
ZIDOVUDINE IS EFFECTIVE IN ALL RACES
JWatch General 1991;1991:1-1.
FULL TEXT
Zidovudine Does It Work for Everyone?
Smith
JAMA 1991;266:2750-2751.
ABSTRACT
|
